QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

Lung cancer is the leading cause of cancer-related deaths worldwide. According to the 2023 global cancer statistics, there are approximately 2.47 million new cases and 1.76 million deaths of lung cancer annually, accounting for 18.4% of all cancer deaths. Among them, driver gene negative NSCLC accounts for about 30% -40% of all NSCLC. In China, the incidence rate and mortality of lung cancer rank first. In 2022, there will be about 870000 new cases and 760000 deaths. In Chinese NSCLC patients, the EGFR mutation rate is about 50%, ALK fusion is about 5%, other mutations (ROS1, RET, etc.) are ab

Trial Details

NCT ID
NCT07330596
Phase
PHASE2
Sponsor
Anhui Provincial Cancer Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • QL1706 combined with Chemotherapy
  • Chemotherapy
Locations (sample)
  • Hefei, China|31.86389,117.28083

Key Eligibility Criteria

  • Voluntarily participate in the research and sign an informed consent form; Age ≥ 18 years old, ≤ 75 years old;
  • Diagnosed with NSCLC through histology or cytology;
  • No EGFR sensitive mutations or ALK gene translocation changes;
  • Previously received PD-1/PD-L1 inhibitors combined with platinum based dual therapy or sequential therapy as first-line treatment for advanced meta…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →